AICAR vs Ghrelin

Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide; acadesine) is a non-peptide, cell-permeable nucleoside analog and prodrug that is phosphorylated intracellularly to its monophosphate form (ZMP), which mimics AMP to activate AMP-activated protein kinase (AMPK) — the primary cellular energy sensor — producing metabolic effects that partially phenocopy those of exercise and caloric restriction. AMPK activation by AICAR upregulates GLUT4 expression and glucose uptake, stimulates fatty acid oxidation, increases mitochondrial biogenesis via PGC-1alpha, and suppresses hepatic gluconeogenesis; a landmark 2008 preclinical study demonstrated that AICAR administration in sedentary mice increased running endurance and activated exercise-related gene expression programs without physical training, generating significant research interest in its potential as an exercise mimetic. The only published human clinical trial involved intravenous AICAR administration in patients with type 2 diabetes, where it reduced hepatic glucose output and inhibited whole-body lipolysis via AMPK, validating the pathway pharmacology in humans; the exercise-mimetic effects observed in rodents have not been replicated or evaluated in any human study, and no oral or injectable form has been assessed for human performance use in published research. AICAR is not a peptide and has no FDA approval; it is prohibited in sport by WADA, available only as a research chemical, and all performance-related interest derives from preclinical rodent data that has not been translated to human investigation; the IV metabolic effects in diabetic patients should not be extrapolated to an athletic or performance context.

Must be acylated at Ser3 (by GOAT enzyme) for GHSR-1a binding. Receptor activation in the pituitary stimulates GH release; hypothalamic action via NPY/AgRP neurons increases appetite and reduces energy expenditure.

Ghrelin is an endogenous 28-amino-acid peptide hormone produced primarily by X/A-like cells of the gastric fundus, characterized by a unique octanoyl modification at Ser3 required for GHS-R1a receptor binding; it is the endogenous ligand for the growth hormone secretagogue receptor and functions as a dual regulator of GH secretion and energy homeostasis. Ghrelin acts centrally via hypothalamic GHS-R1a receptors to potently stimulate GH release from the pituitary and to promote appetite through NPY/AgRP pathway activation, and has peripheral effects on gastric motility and insulin secretion, establishing it as a key integrator of nutritional status, GH axis activity, and energy balance. The pharmacology of GHS-R1a activation in humans is validated through macimorelin (Macrilen), an FDA-approved oral ghrelin receptor agonist; Phase 1 and Phase 2 randomized controlled trials of macimorelin demonstrated robust and reliable GH stimulation in adults, supporting FDA approval in 2017 for the diagnosis of adult GH deficiency and confirming the human physiological relevance of ghrelin receptor activation. Ghrelin itself is not therapeutically administered; it has a very short plasma half-life and the active acylated form is rapidly degraded in circulation; FDA-approved ghrelin receptor agonists require prescription and are indicated for diagnostic rather than therapeutic use, while ghrelin peptide is used exclusively as a research tool compound in neuroendocrine pharmacology studies.